Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yasuhiro Hagiwara"'
Autor:
Yoshikuni Kawaguchi, Norihiro Kokudo, Shuichiro Shiina, Simone Famularo, Tomoaki Ichikawa, Masatoshi Kudo, Kiyoshi Hasegawa, Shoji Kubo, Yasuhiro Hagiwara, Takamichi Murakami, Namiki Izumi, Tadatoshi Takayama, Yutaka Matsuyama, Takashi Kokudo, Ryosuke Tateishi, Jean Nicolas Vauthey, Andrea Ruzzenente, Michiie Sakamoto, Elena Panettieri, Felice Giuliante, Mario De Bellis, Fabrizio Romano, Osamu Nakashima, Luciano De Carlis, Alfredo Guglielmi
Publikováno v:
The American journal of gastroenterology. 116(8)
INTRODUCTION Most studies predicting survival after resection, transarterial chemoembolization (TACE), and ablation analyzed diameter and number of hepatocellular carcinomas (HCCs) as dichotomous variables, resulting in an underestimation of risk var
Autor:
Hirotsugu Isaka, Yasuhiro Hagiwara, Hirofumi Mukai, Yutaka Matsuyama, Kentaro Imi, Kenichi Watanabe
Publikováno v:
Oncology. 93:315-322
Objective: We assessed the impact of treatment preferences in second-line chemotherapy on breast cancer prognosis using the SELECT BC study. Methods: The SELECT BC study was performed in patients with HER2-negative metastatic breast cancer treated wi
Publikováno v:
Intensive care medicine. 46(1)
The development of new-onset atrial fibrillation (AF) in critically ill patients may be associated with poor outcomes. However, it is unknown whether sustained new-onset AF contributes to worse outcome. The aim of this study was to assess whether sus
Autor:
Takayuki Yoshino, Takeharu Yamanaka, J. Furuse, Eiji Oki, Yasushi Tsuji, Masako Asayama, Yoshinori Kagawa, T. Kato, Yasuo Komatsu, Takashi Ando, K. Shitara, Hiroyuki Okuda, Kohei Akiyoshi, Yasuo Ohashi, Yoshimitsu Kobayashi, Yasuhiro Hagiwara, K. Shinozaki, Tadamichi Denda
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(2)
Background The objective of this randomized phase II trial was to evaluate efficacy and safety of the therapeutic sequence of regorafenib followed by cetuximab, compared with cetuximab followed by regorafenib, as the current standard sequence for met
Autor:
Koji Imai, Katsuhiko Uesaka, Yuji Kaneoka, Ryuzo Yamaguchi, Masaru Konishi, Yasuhiro Shimizu, Soichiro Morinaga, Hirohiko Sakamoto, Yukiyasu Okamura, Osamu Kainuma, Shoichi Hishinuma, Takeshi Sudo, Yasuo Ohashi, Akira Fukutomi, Shoji Nakamori, Naohiro Sata, Hitoshi Ojima, Yasuhiro Hagiwara, Satoshi Hirano, Ippei Matsumoto, Narikazu Boku
Publikováno v:
European journal of cancer (Oxford, England : 1990). 93
Background Adjuvant chemotherapy with S-1 for resected pancreatic cancer demonstrated survival benefits compared with gemcitabine in the JASPAC 01 trial. We investigated the effect of these agents on health-related quality of life (HRQOL) of patients